Cosette Patent-Cliff Exposure & CMS Drug Spending Portfolio

Cosette (US): 14 reconciled FDA prescription therapies (3.0% 2025 to 2030 cliff risk), $66.7M 2024 CMS Part D & Medicaid spend, and 47 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies14
2025 to 2030 Patent-Cliff Revenue Exposure3.0%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$66.7M
2024 Medicare Part D Spend$52.2M
2024 Medicaid Spend$14.6M
California HCAI SB 17 Filings47 WAC filings (max 32.9% 2-yr change)